Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511640 · ClinicalTrials.gov registry record · Early Phase 1
Behavioral Effects of Pregabalin and Cannabis
A Early Phase 1 study of Cannabis Use Disorders, sponsored by Joshua A. Lile, Ph.D..
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01511640 is a Early Phase 1 study of Cannabis Use Disorders that has completed, run by Joshua A. Lile, Ph.D.. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01511640, a Early Phase 1 study of Cannabis Use Disorders, has completed, sponsored by Joshua A. Lile, Ph.D..
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use disorders. The purpose of the present study is to evaluate the ability of pregabalin to reduce cannabis use thereby evaluating its effectiveness as a medication for cannabis-use disorders.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pregabalin
Study Locations (1)
Kentucky
- Laboratory of Human Behavioral Pharmacology - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2020-03-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511640
The ClinicalTrials.gov registry entry for NCT01511640 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua A. Lile, Ph.D., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cannabis Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01511640 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT01511640 about?
NCT01511640 is a clinical study titled "Behavioral Effects of Pregabalin and Cannabis". Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use di...
What is the current status of trial NCT01511640?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2017-02-01. Estimated completion is 2020-03-15.
What conditions does trial NCT01511640 study?
This clinical trial studies the following conditions: Cannabis Use Disorders.
What interventions are being tested in trial NCT01511640?
The interventions under investigation include: Placebo (DRUG), Pregabalin (DRUG).
Who is sponsoring clinical trial NCT01511640?
This trial is sponsored by Joshua A. Lile, Ph.D., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01511640 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.